Automation and Shift in Advanced Therapies (ATMPs):The commercialization of cell and gene therapies is forcing a structural evolution. For cell therapies, the focus centers on heightened process automation and a strategic pivot from autologous treatments toward allogeneic (off-the-shelf) models. Meanwhile, gene therapies and nucleic acid applications are successfully expanding beyond rare diseases and infectious outbreaks to target broader, high-prevalence medical conditions.
compsoc-dinners@lists.ox.compsoc.net